STEPS

New Drug Reviews

Saxagliptin (Onglyza) for Type 2 Diabetes Mellitus



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2010 Jun 15;81(12):1483-1484.

Saxagliptin (Onglyza) is the second oral dipeptidyl peptidase–4 (DPP-4) inhibitor to be marketed for the treatment of type 2 diabetes mellitus in adults. DPP-4 is the enzyme responsible for rapidly degrading incretin hormones released by the gut in response to meals.1,2 The incretin hormones contribute to postmeal insulin secretion, as well as inhibit glucagon release, improve satiety, and slow gastric emptying. By inhibiting DPP-4, saxagliptin prolongs the glucose-lowering effects of the incretin hormones. Saxagliptin is labeled for use as monotherapy or in combination with metformin (Glucophage), sulfonylureas, or thiazolidinediones.3

Drug Starting dosage Dose form Approximate monthly cost*

Saxagliptin (Onglyza)

2.5 or 5.0 mg once daily; 2.5 mg in patients with moderate to severe renal dysfunction

2.5- and 5.0-mg tablets

$203


*— Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed May 18, 2010).

Drug Starting dosage Dose form Approximate monthly cost*

Saxagliptin (Onglyza)

2.5 or 5.0 mg once daily; 2.5 mg in patients with moderate to severe renal dysfunction

2.5- and 5.0-mg tablets

$203


*— Estimated retail price of one month's treatment based on information obtained at http://www.drugstore.com (accessed May 18, 2010).

SAFETY

Few adverse effects have been associated with saxagliptin. Unlike some other oral hypoglycemics, when saxagliptin is used alone it does not increase the likelihood of hypoglycemia.1,3,4 When used as monotherapy or add-on therapy with metformin or thiazolidinediones, saxagliptin has an incidence of hypoglycemia that is comparable with placebo.1,37 The manufacturer states that hypoglycemia is more common when saxagliptin is combined with glyburide (formerly Micronase), although the frequency is not significantly higher than with glyburide alone (13.3 to 14.6 percent versus 10.1 percent, respectively).2,3 In 0.5 to 1.5 percent of patients, saxagliptin decreases lymphocyte count and causes lymphocytopenia (i.e., lymphocyte count of 750 cells per μL [0.75 × 109 per L] or less). Decreases in lymphocyte count have not caused any clinical sequelae; however, the effects of saxagliptin in patients with preexisting lymphocyte abnormalities (e.g., human immunodeficiency virus infection) are unknown.3

Patients with moderate to severe renal dysfunction (creatinine clearance of less than 50 mL per minute per 1.73 m2 [0.83 mL per second per m2]) require a dosage reduction to 2.5 mg once daily. The lower dosage also should be used in patients receiving strong cytochrome P450 3A4 and 3A5 inhibitors, such as clarithromycin (Biaxin), ketoconazole, and the antivirals ritonavir (Norvir), nelfinavir (Viracept), and atazanavir (Reyataz). Saxagliptin is U.S. Food and Drug Administration pregnancy category B.3

TOLERABILITY

Saxagliptin is well tolerated and produces bothersome adverse effects to a similar extent as placebo.17 Saxagliptin does not seem to promote weight gain.1,4,6 Up to 3.3 percent of patients will stop taking saxagliptin because of adverse effects. The rate of discontinuation is highest with the 5.0-mg dose, compared with the 2.5-mg dose (2.2 percent) or placebo (1.8 percent).3

EFFECTIVENESS

On average, saxagliptin monotherapy will lower the A1C level by 0.4 to 0.9 percent.1,4 Adding saxagliptin to metformin, glyburide, or a thiazolidinedione will reduce the A1C level by an additional 0.6 to 0.9 percent.2,6,7 Saxagliptin monotherapy will lower the average fasting glucose level by 9 to 22 mg per dL (0.50 to 1.22 mmol per L) and the postprandial glucose level by 24 to 45 mg per dL (1.33 to 2.50 mmol per L).1,3,4 When used as add-on therapy, saxagliptin causes similar reductions in fasting and postprandial glucose levels.2,6,7

Efficacy trials with saxagliptin were no longer than six months in duration, and long-term studies of effectiveness and safety are currently ongoing. The effect of saxagliptin on diabetes-related morbidity and mortality, or all-cause mortality, is not known. Clinical trials have not investigated the combination of saxagliptin and insulin.

PRICE

A 30-day supply of the 2.5- or 5.0-mg tablets of saxagliptin costs approximately $203. A one-month supply of sitagliptin (Januvia), the other available DPP-4 inhibitor, costs $207 for the 100-mg tablets. As a comparison, the cost of metformin is $32 (brand: $141) for 60 (a one-month supply) of the 1,000-mg tablets.

SIMPLICITY

Saxagliptin is available in 2.5- and 5.0-mg tablets. Saxagliptin is taken once daily without regard to meals. There are no known contraindications to saxagliptin therapy.3

Bottom Line

Saxagliptin lowers A1C levels to a lesser extent and is much more expensive than first-line therapy with metformin. Its ability to decrease diabetes-related complications, including mortality, is not known. It is a DPP-4 inhibitor that has a more significant drug interaction profile than sitagliptin and offers little cost advantage. For these reasons, saxagliptin should be reserved as an alternative therapy for patients who cannot tolerate other treatments for type 2 diabetes or in whom other treatments fail.

Address correspondence to Karen Whalen, PharmD, BCPS, CDE, at whalen@cop.ufl.edu. Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411.

2. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–406.

3. Onglyza (saxagliptin) tablets [prescribing information]. Princeton, N.J.: Bristol-Myers Squibb Company; 2009. http://packageinserts.bms.com/pi/pi_onglyza.pdf. Accessed January 29, 2010.

4. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386.

5. Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622.

6. DeFronzo RA, Hissa MN, Garber AJ, et al. Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655.

7. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series coordinator for AFP is Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Mass.

A collection of STEPS published in AFP is available at http://www.aafp.org/afp/steps.



Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article